Smith & Nephew plc (NYSE:SNN) to Issue Semi-Annual Dividend of $0.28

Smith & Nephew plc (NYSE:SNN) declared a Semi-Annual dividend on Wednesday, July 29th, Zacks reports. Investors of record on Friday, October 2nd will be paid a dividend of 0.278 per share by the medical equipment provider on Wednesday, October 28th. The ex-dividend date is Thursday, October 1st.

Smith & Nephew has raised its dividend payment by an average of 16.3% per year over the last three years and has increased its dividend every year for the last 1 years. Smith & Nephew has a payout ratio of 58.4% meaning its dividend is sufficiently covered by earnings. Analysts expect Smith & Nephew to earn $2.02 per share next year, which means the company should continue to be able to cover its $0.90 annual dividend with an expected future payout ratio of 44.6%.

Shares of Smith & Nephew stock traded down $0.65 during trading on Friday, hitting $40.27. 5,809 shares of the company were exchanged, compared to its average volume of 439,660. The company has a quick ratio of 1.03, a current ratio of 2.06 and a debt-to-equity ratio of 0.38. Smith & Nephew has a fifty-two week low of $26.07 and a fifty-two week high of $52.26. The stock has a market capitalization of $17.78 billion, a price-to-earnings ratio of 20.06, a P/E/G ratio of 6.86 and a beta of 0.56. The firm has a 50 day moving average price of $40.15 and a 200 day moving average price of $41.62.

Several research analysts recently issued reports on SNN shares. JPMorgan Chase & Co. restated a “neutral” rating on shares of Smith & Nephew in a research report on Thursday. Exane BNP Paribas downgraded Smith & Nephew from a “neutral” rating to an “underperform” rating in a research report on Friday, June 5th. BNP Paribas downgraded Smith & Nephew from a “neutral” rating to an “underperform” rating in a report on Friday, June 5th. Zacks Investment Research downgraded Smith & Nephew from a “hold” rating to a “strong sell” rating in a report on Friday. Finally, Citigroup downgraded Smith & Nephew from a “buy” rating to a “neutral” rating in a report on Tuesday, April 14th. Three investment analysts have rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company. Smith & Nephew presently has an average rating of “Hold” and an average target price of $48.00.

About Smith & Nephew

Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.

Read More: Catch-Up Contributions

Dividend History for Smith & Nephew (NYSE:SNN)

Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.